Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 15;40(7):206.
doi: 10.1007/s12032-023-02066-x.

NK cells direct the perspective approaches to cancer immunotherapy

Abduladheem Turki Jalil  1 , Mohanad Ali Abdulhadi  2 , Farah A Al-Marzook  3 , Manar Mohammed Hizam  4 , Sada Jasim Abdulameer  5 , Abdul Kareem J Al-Azzawi  6 , Rahman S Zabibah  7 , Ali A Fadhil  8
Affiliations
Review

NK cells direct the perspective approaches to cancer immunotherapy

Abduladheem Turki Jalil et al. Med Oncol. .

Abstract

Natural killer (NK) cells are innate immune cells with cytotoxic potentials to kill cancerous cells in several mechanisms, which could be implied for cancer therapy. While potent, their antitumor activities specially for solid tumors impaired by inadequate tumor infiltration, suppressive tumor microenvironment, cancer-associated stroma cells, and tumor-supportive immune cells. Therefore, manipulating or reprogramming these barriers by prospective strategies might improve current immunotherapies in the clinic or introduce novel NK-based immunotherapies. NK-based immunotherapy could be developed in monotherapy or in combination with other therapeutic regimens such as oncolytic virus therapy and immune checkpoint blockade, as presented in this review.

Keywords: Cancer immunotherapy; Chimeric antigen receptor; Oncolytic viruses; Targeted therapy; Tumor microenvironment.

PubMed Disclaimer

References

    1. Achmad H, Ibrahim YS, Al-Taee MM, Gabr GA, Riaz MW, Alshahrani SH, et al. Nanovaccines in cancer immunotherapy: focusing on dendritic cell targeting. Int Immunopharmacol. 2022;113:109434. - PubMed
    1. Esfahani K, Roudaia L, Buhlaiga N, Del Rincon S, Papneja N, Miller W. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(s2):87–97.
    1. DeW E. Driving T-cell immunotherapy to solid tumors. Nat Biotechnol. 2018;36(3):215–9.
    1. Dianat-Moghadam H, Mahari A, Salahlou R, Khalili M, Azizi M, Sadeghzadeh H. Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy. Stem Cell Res Ther. 2022;13(1):1–12.
    1. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discovery. 2015;14(8):561–84. - PubMed

Substances

LinkOut - more resources